_version_ 1784633181157195776
author Okamoto, Akinao
Fujigaki, Hidetsugu
Iriyama, Chisako
Goto, Naoe
Yamamoto, Hideyuki
Mihara, Keichiro
Inaguma, Yoko
Miura, Yasuo
Furukawa, Katsuya
Yamamoto, Yukiya
Akatsuka, Yoshiki
Kasahara, Senji
Miyao, Kotaro
Tokuda, Masutaka
Sato, Seiko
Mizutani, Yuki
Osawa, Michiko
Hattori, Keiko
Iba, Sachiko
Kajiya, Ryoko
Okamoto, Masataka
Saito, Kuniaki
Tomita, Akihiro
author_facet Okamoto, Akinao
Fujigaki, Hidetsugu
Iriyama, Chisako
Goto, Naoe
Yamamoto, Hideyuki
Mihara, Keichiro
Inaguma, Yoko
Miura, Yasuo
Furukawa, Katsuya
Yamamoto, Yukiya
Akatsuka, Yoshiki
Kasahara, Senji
Miyao, Kotaro
Tokuda, Masutaka
Sato, Seiko
Mizutani, Yuki
Osawa, Michiko
Hattori, Keiko
Iba, Sachiko
Kajiya, Ryoko
Okamoto, Masataka
Saito, Kuniaki
Tomita, Akihiro
author_sort Okamoto, Akinao
collection PubMed
description
format Online
Article
Text
id pubmed-8759802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-87598022022-01-18 CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma Okamoto, Akinao Fujigaki, Hidetsugu Iriyama, Chisako Goto, Naoe Yamamoto, Hideyuki Mihara, Keichiro Inaguma, Yoko Miura, Yasuo Furukawa, Katsuya Yamamoto, Yukiya Akatsuka, Yoshiki Kasahara, Senji Miyao, Kotaro Tokuda, Masutaka Sato, Seiko Mizutani, Yuki Osawa, Michiko Hattori, Keiko Iba, Sachiko Kajiya, Ryoko Okamoto, Masataka Saito, Kuniaki Tomita, Akihiro Blood Adv Research Letter American Society of Hematology 2022-05-31 /pmc/articles/PMC8759802/ /pubmed/35026843 http://dx.doi.org/10.1182/bloodadvances.2021006302 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://www.ncbi.nlm.nih.gov/pmc/pmcdoc/tagging-guidelines/article/tags.html#el-licenseThis article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Research Letter
Okamoto, Akinao
Fujigaki, Hidetsugu
Iriyama, Chisako
Goto, Naoe
Yamamoto, Hideyuki
Mihara, Keichiro
Inaguma, Yoko
Miura, Yasuo
Furukawa, Katsuya
Yamamoto, Yukiya
Akatsuka, Yoshiki
Kasahara, Senji
Miyao, Kotaro
Tokuda, Masutaka
Sato, Seiko
Mizutani, Yuki
Osawa, Michiko
Hattori, Keiko
Iba, Sachiko
Kajiya, Ryoko
Okamoto, Masataka
Saito, Kuniaki
Tomita, Akihiro
CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
title CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
title_full CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
title_fullStr CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
title_full_unstemmed CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
title_short CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma
title_sort cd19-positive lymphocyte count is critical for acquisition of anti-sars-cov-2 igg after vaccination in b-cell lymphoma
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759802/
https://www.ncbi.nlm.nih.gov/pubmed/35026843
http://dx.doi.org/10.1182/bloodadvances.2021006302
work_keys_str_mv AT okamotoakinao cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT fujigakihidetsugu cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT iriyamachisako cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT gotonaoe cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT yamamotohideyuki cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT miharakeichiro cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT inagumayoko cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT miurayasuo cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT furukawakatsuya cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT yamamotoyukiya cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT akatsukayoshiki cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT kasaharasenji cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT miyaokotaro cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT tokudamasutaka cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT satoseiko cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT mizutaniyuki cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT osawamichiko cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT hattorikeiko cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT ibasachiko cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT kajiyaryoko cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT okamotomasataka cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT saitokuniaki cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma
AT tomitaakihiro cd19positivelymphocytecountiscriticalforacquisitionofantisarscov2iggaftervaccinationinbcelllymphoma